Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06624085 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Phase 1 study of Lymphoma, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 15
- Study locations
NCT06624085 is a Phase 1 study of Lymphoma that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 50 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT06624085, a Phase 1 study of Lymphoma, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Glofitamab
- DRUG Oxaliplatin
- DRUG Gemcitabine
- DRUG Tocilizumab
Study Locations (15)
California
- UC San Diego Moores Cancer Center - La Jolla
- Saddleback Memorial Medical Center - Laguna Hills
- University of California Los Angeles (UCLA) - Cancer Care - Santa Monica - Santa Monica
Texas
- Renovatio Clinical - El Paso - El Paso
- Baylor College of Medicine - Houston
- Renovatio Clinical - The Woodlands
District of Columbia
- Georgetown University - Washington D.C.
Florida
- AdventHealth Cancer Institute - Orlando
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Illinois
- University of Illinois Cancer Center - Chicago
Kansas
- Kansas City VA Medical Center - Kansas City
Maryland
- Walter Reed National Military Medical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06624085
The ClinicalTrials.gov registry entry for NCT06624085 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT06624085 reports 15 study locations spanning 11 distinct geographic areas - top geographies include California, Texas, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06624085 about?
NCT06624085 is a clinical study titled "A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma". The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
What is the current status of trial NCT06624085?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-04-28. Estimated completion is 2030-03-31.
What conditions does trial NCT06624085 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT06624085?
The interventions under investigation include: Obinutuzumab (DRUG), Glofitamab (DRUG), Oxaliplatin (DRUG), Gemcitabine (DRUG), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT06624085?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06624085 being conducted?
This trial has 15 study locations across California, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.